EuropaWire7d
Sanofi’s Sarclisa Receives Approval in China for Newly Diagnosed Multiple Myeloma Treatment
Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...
Inside the UK's 'Blue Zones' cities - see list of Britain's healthiest places
A recent study has ranked the UK's healthiest cities, considering factors such as diet, exercise, smoking and sleeping habits ...
UK's 'Blue Zones' cities named healthiest places to live - check where you live
Some areas of Britain are more like a Blue Zone than others - and it's not a coincidence that people living in these regions ...
Pharmabiz25d
China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma
This approval is based on results from the pivotal ICARIA-MM phase 3 study, using the China-based IsaFiRsT real-world study as bridging data. The ICARIA-MM study demonstrated Sarclisa in combination ...
Business Insider26d
Sanofi's Sarclisa Gets First Approval In China For Relapsed Or Refractory Multiple Myeloma In Adults
The approval is based on results from the pivotal ICARIA-MM phase 3 study, using the China-based IsaFiRsT real-world study as bridging data. The ICARIA-MM study demonstrated Sarclisa in ...
PharmiWeb26d
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved ...
The Pharma Letter26d
BRIEF—Sarclisa obtains first approval in China
This approval is based on results from the pivotal ICARIA-MM Phase III study, using the China-based IsaFiRsT real-world study as bridging data. The ICARIA-MM study demonstrated Sarclisa in combination ...